Dolby Laboratories filings document the regulatory disclosures of a technology licensing and cinema-products company whose Class A common stock trades on the New York Stock Exchange under DLB. Recent Form 8-K reports furnish quarterly and annual financial results, dividend declarations for Class A and Class B common stock, and related exhibits.
The company’s proxy and governance filings cover director elections, advisory executive-compensation votes, auditor ratification and executive incentive compensation arrangements. The filings also describe Dolby’s dual-class voting structure, with Class A and Class B common stock voting together on most stockholder matters except where law requires otherwise.
Dolby Laboratories, Inc. (DLB) reported that its President and CEO, Marc Whitten, received two equity awards on September 15, 2026. He was granted 160,256 restricted stock units under Dolby’s 2026 Inducement Stock Plan that vest in four equal installments starting March 15, 2027 and then on each six‑month anniversary, subject to continued employment. Each unit converts into one share of Class A common stock upon vesting and remains subject to forfeiture until it vests.
Whitten also received 600,000 performance-based restricted stock units under the same plan, split into tranches of 150,000, 150,000, 100,000, 100,000 and 100,000 units. These tranches become eligible to vest if Dolby’s stock price reaches $75, $100, $125, $150 and $175, respectively, averaged over a consecutive 60 trading-day period within a five-year performance window, with adjustments for dividends and capitalization changes. Eligible units vest upon certification of each stock-price goal, contingent on Whitten’s continued service as CEO.
Dolby Laboratories, Inc. (symbol: DLB) is the issuer of record for a Form 4 filing submitted to the SEC. Couling John D reported acquisition or exercise transactions in this Form 4 filing.
Dolby Laboratories, Inc. executive John D. Couling, SVP, Entertainment, received an equity compensation grant of 48,076 restricted stock units (RSUs) of Class A Common Stock on September 15, 2026 under the company’s 2020 Stock Plan. All RSUs vest on September 15, 2028, subject to his continued service, with each unit delivering one share upon vesting. Following this award, he holds 166,803 Class A shares in total, including 103,190 shares underlying unvested RSUs that remain subject to forfeiture. No Rule 10b5-1 trading plan is reported.
Dolby Laboratories, Inc. (DLB) reported that executive vice president, general counsel and secretary Mark Andrew Sherman received a grant of 48,076 restricted stock units of Class A common stock on September 15, 2026 under the company’s 2020 Stock Plan. These units vest 100% on September 15, 2028, contingent on his continued service, with each unit representing a right to receive one Class A share upon vesting. Following this award, Sherman holds 119,024 Class A shares directly, including 101,712 shares underlying unvested restricted stock units and 385 shares acquired through the Employee Stock Purchase Plan. No Rule 10b5-1 trading plan is reported.
Dolby Laboratories, Inc. (DLB) reported that John D. Couling, SVP, Entertainment, exercised stock options and sold shares on September 1, 2026 under an affirmed Rule 10b5-1 trading plan. He exercised options for 7,667 shares of Class A Common Stock at an exercise price of $45.50 per share and received 7,667 shares. On the same date, he sold 7,667 shares of Class A Common Stock at a weighted average price of $61.045 per share in multiple transactions priced between $60.65 and $61.25. The exercised options were part of an option originally granted for 46,000 shares, and his holdings after the transactions include 55,114 shares underlying restricted stock units that remain subject to forfeiture until vesting.
Dolby Laboratories, Inc. (DLB) received a notice under Rule 144 that officer John Couling plans to sell common stock. The notice covers 7,667 shares to be sold through Morgan Stanley Smith Barney LLC on or about September 1, 2026, following a stock option exercise. The filing reports an aggregate market value of about $468,032.02 for these shares and notes 59,416,894 shares of the same class outstanding. Couling also reported prior Rule 144 sales of 7,667 shares each on July 1, 2026 and August 3, 2026.
Dolby Laboratories, Inc. (DLB) reported insider transactions involving long‑time significant holder Dagmar Dolby and related trusts on August 28, 2026. The Dagmar Dolby Trust converted 300,000 shares of Class B Common Stock into 300,000 shares of Class A Common Stock at no cost and gifted all such Class A shares to an unaffiliated charitable organization, a transaction the footnotes state is exempt from Section 16(b) under Rule 16b-5.
On the same date, the Dagmar Dolby Trust restructured ownership by contributing a total of 2,000,000 Class B shares (convertible 1‑for‑1 into Class A) for no value, with 1,000,000 shares moved to the Dagmar Dolby 2026 Trust AA‑2 and 1,000,000 shares to the Dagmar Dolby 2026 Trust BB, described as tax and estate planning transfers. All reported holdings are indirect, largely through trusts and LLCs, and the reporting persons disclaim beneficial ownership beyond their pecuniary interests.
Dolby Laboratories, Inc. (DLB) filed an initial statement of beneficial ownership (Form 3) for Marc Whitten. He is listed as a director and as an officer
Dolby Laboratories, Inc. (DLB) reported that Ryan Nicholson, VP, CAO and Corporate Controller, sold 1,183 shares of Class A Common Stock on 2026-08-25 in an open market or private transaction at a price of $65.2773 per share. Following this sale, Nicholson held a reported total of 34,453 shares of Class A Common Stock, which the company notes includes 19,303 shares underlying restricted stock units that remain subject to forfeiture until they vest.
Dolby Laboratories, Inc. (DLB) announced a CEO leadership transition, appointing Marc Whitten as President, Chief Executive Officer and director effective August 27, 2026, following the retirement of long-time CEO Kevin Yeaman, who will remain as a paid advisor through 2027 under a consulting agreement.
Whitten’s employment agreement provides a $1,000,000 annual salary, a target annual bonus equal to 100% of salary beginning in fiscal 2027 (with fiscal 2027 paid at target), a $2,100,000 sign-on bonus subject to repayment conditions, and up to $200,000 in relocation reimbursement, plus significant equity awards under a new inducement plan and participation in the 2027 equity cycle. He is entitled to enhanced cash severance, COBRA reimbursements and equity vesting upon qualifying terminations, with higher benefits in connection with a Change in Control.
Yeaman’s transition package includes $40,000 per month for six months of consulting, continued equity vesting during the consulting period, a 2026 bonus based on actual performance, COBRA reimbursement through December 31, 2027, up to $200,000 in coaching and $15,000 for legal fees. The Board also adopted a 2026 Inducement Stock Plan reserving 2,500,000 Class A shares, and approved one-time $3,000,000 retention RSU awards for two senior executives, vesting after two years.
Dolby Laboratories, Inc. (DLB) is the issuer for a proposed sale of its common stock under Rule 144 by officer Ryan H. Nicholson. Nicholson has filed to sell 1,183 shares through Morgan Stanley Smith Barney LLC, and within the past three months has already sold additional Dolby shares for disclosed amounts.